FI3765012T3 - Dgat1-inhibiittoreita ummetuksen hoitoon - Google Patents

Dgat1-inhibiittoreita ummetuksen hoitoon

Info

Publication number
FI3765012T3
FI3765012T3 FIEP19767984.8T FI19767984T FI3765012T3 FI 3765012 T3 FI3765012 T3 FI 3765012T3 FI 19767984 T FI19767984 T FI 19767984T FI 3765012 T3 FI3765012 T3 FI 3765012T3
Authority
FI
Finland
Prior art keywords
constipation
use according
pradigastat
ester
pharmaceutically acceptable
Prior art date
Application number
FIEP19767984.8T
Other languages
English (en)
Finnish (fi)
Inventor
Brian K Hubbard
Michael H Serrano-Wu
Original Assignee
Serleva Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serleva Inc filed Critical Serleva Inc
Application granted granted Critical
Publication of FI3765012T3 publication Critical patent/FI3765012T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP19767984.8T 2018-03-16 2019-03-15 Dgat1-inhibiittoreita ummetuksen hoitoon FI3765012T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (1)

Publication Number Publication Date
FI3765012T3 true FI3765012T3 (fi) 2026-04-17

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19767984.8T FI3765012T3 (fi) 2018-03-16 2019-03-15 Dgat1-inhibiittoreita ummetuksen hoitoon

Country Status (18)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
DK (1) DK3765012T3 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
ATE406448T1 (de) 1998-06-24 2008-09-15 David Gladstone Inst Diacylglycerin o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006113919A2 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2418202B1 (en) * 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
NZ602125A (en) * 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
CN102869645A (zh) * 2010-04-08 2013-01-09 美迪诺亚公司 用于治疗肠易激综合征的方法和组合物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
BR112016015851A2 (pt) * 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора

Also Published As

Publication number Publication date
MY205335A (en) 2024-10-16
US20240293376A1 (en) 2024-09-05
US11224590B2 (en) 2022-01-18
TWI704917B (zh) 2020-09-21
US20190282549A1 (en) 2019-09-19
US20220193044A1 (en) 2022-06-23
DK3765012T3 (da) 2026-04-27
EP3765012B1 (en) 2026-03-04
BR112020018790A2 (pt) 2020-10-13
JP7527984B2 (ja) 2024-08-05
US20260000651A1 (en) 2026-01-01
KR20200136428A (ko) 2020-12-07
EP3765012A1 (en) 2021-01-20
MX2020009604A (es) 2023-01-25
CN111936137A (zh) 2020-11-13
KR102747096B1 (ko) 2024-12-26
PE20210158A1 (es) 2021-01-26
SG11202008971VA (en) 2020-10-29
EP3765012A4 (en) 2021-12-15
AU2019234956B2 (en) 2025-01-30
WO2019178492A1 (en) 2019-09-19
JP2021518431A (ja) 2021-08-02
IL277332B2 (en) 2025-01-01
IL277332B1 (en) 2024-09-01
CN111936137B (zh) 2023-09-08
EA202092190A1 (ru) 2020-11-19
IL277332A (en) 2020-10-29
US12343334B2 (en) 2025-07-01
PH12020551468A1 (en) 2021-09-01
CA3093970A1 (en) 2019-09-19
AU2019234956A1 (en) 2020-10-01
TW201944995A (zh) 2019-12-01
US11819495B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
FI4054719T3 (fi) Ras-estäjiä
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MY199409A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2007111945A3 (en) Method for management of diarrhea
NZ603837A (en) Novel nicotinamide derivative or salt thereof
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
SI3009428T1 (en) DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
PH12019501802A1 (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
PH12017500724A1 (en) Carbazole derivatives
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
GEAP202215588A (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
FI3765012T3 (fi) Dgat1-inhibiittoreita ummetuksen hoitoon
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
ZA202101118B (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
MX2022003095A (es) Tratamiento de cancer mediante una combinacion que comprende un inhibidor de la multi-tirosina quinasa y un inhibidor de puntos de control inmunitarios.
WO2017029588A3 (en) Mdm2 inhibitors for treating uveal melanoma